Could adding erlotinib to chemo shrink head and neck tumors better?
NCT ID NCT01927744
First seen Jan 09, 2026 · Last updated Jun 16, 2026 · Updated 23 times
Summary
This study tested whether adding the targeted drug erlotinib to standard chemotherapy (docetaxel plus cisplatin or carboplatin) could improve tumor shrinkage before surgery in people with advanced head and neck cancer. About 55 adults with surgically removable tumors took part. The main goal was to see if the combination led to fewer live cancer cells left in the removed tumor compared to chemo plus a placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.